ATE228358T1 - Neue verwendung einer klasse von peptidverbindungen zur behandlung von allodynie oder andere arten von chronischen oder phantomschmerzen - Google Patents

Neue verwendung einer klasse von peptidverbindungen zur behandlung von allodynie oder andere arten von chronischen oder phantomschmerzen

Info

Publication number
ATE228358T1
ATE228358T1 AT01107026T AT01107026T ATE228358T1 AT E228358 T1 ATE228358 T1 AT E228358T1 AT 01107026 T AT01107026 T AT 01107026T AT 01107026 T AT01107026 T AT 01107026T AT E228358 T1 ATE228358 T1 AT E228358T1
Authority
AT
Austria
Prior art keywords
treatment
pain
phantomatic
allodynia
chronic
Prior art date
Application number
AT01107026T
Other languages
English (en)
Inventor
Norma Dr Selve
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8176866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE228358(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Application granted granted Critical
Publication of ATE228358T1 publication Critical patent/ATE228358T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT01107026T 2001-03-21 2001-03-21 Neue verwendung einer klasse von peptidverbindungen zur behandlung von allodynie oder andere arten von chronischen oder phantomschmerzen ATE228358T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01107026A EP1243263B1 (de) 2001-03-21 2001-03-21 Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen

Publications (1)

Publication Number Publication Date
ATE228358T1 true ATE228358T1 (de) 2002-12-15

Family

ID=8176866

Family Applications (3)

Application Number Title Priority Date Filing Date
AT01107026T ATE228358T1 (de) 2001-03-21 2001-03-21 Neue verwendung einer klasse von peptidverbindungen zur behandlung von allodynie oder andere arten von chronischen oder phantomschmerzen
AT10157595T ATE518532T1 (de) 2001-03-21 2002-03-19 Neue verwendung einer peptidklasse von verbindungen zur behandlung von diabetischem neuropathischem schmerz
AT02727436T ATE490766T1 (de) 2001-03-21 2002-03-19 Neue verwendung einer klasse von peptidverbindungen zur behandlung von allodynie oder andere arten von chronischen oder phatomschmerzen

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT10157595T ATE518532T1 (de) 2001-03-21 2002-03-19 Neue verwendung einer peptidklasse von verbindungen zur behandlung von diabetischem neuropathischem schmerz
AT02727436T ATE490766T1 (de) 2001-03-21 2002-03-19 Neue verwendung einer klasse von peptidverbindungen zur behandlung von allodynie oder andere arten von chronischen oder phatomschmerzen

Country Status (26)

Country Link
US (3) US7875652B2 (de)
EP (3) EP1243263B1 (de)
JP (1) JP4154237B2 (de)
KR (1) KR100557852B1 (de)
CN (1) CN100522149C (de)
AT (3) ATE228358T1 (de)
AU (1) AU2002257680B2 (de)
BR (1) BR0208141A (de)
CA (1) CA2430470C (de)
CZ (1) CZ20032798A3 (de)
DE (2) DE60100055T2 (de)
DK (1) DK1243263T3 (de)
EA (1) EA007600B1 (de)
ES (3) ES2185606T3 (de)
HK (1) HK1048763B (de)
HU (1) HUP0303983A3 (de)
IL (3) IL155585A0 (de)
MX (1) MXPA03006438A (de)
NO (1) NO20033918L (de)
PL (1) PL368408A1 (de)
PT (1) PT1243263E (de)
SI (1) SI21169B (de)
SK (1) SK287714B6 (de)
UA (1) UA73854C2 (de)
WO (1) WO2002074297A1 (de)
ZA (1) ZA200303319B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1243262T3 (da) 2001-03-20 2006-10-02 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter
ES2185606T3 (es) 2001-03-21 2003-05-01 Sanol Arznei Schwarz Gmbh Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma.
JP4664924B2 (ja) * 2003-12-02 2011-04-06 ウーツェーベー ファルマ ゲーエムベーハー 中枢神経因性疼痛の治療のためのペプチド化合物の新規使用
EP1537862A1 (de) * 2003-12-02 2005-06-08 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von zentralen neuropathische-Schmerzen
EP1579858A1 (de) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von diabetishen Neuropathie
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
KR20070007931A (ko) * 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1604654A1 (de) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Dyskynesien
EP1604655A1 (de) 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie
EP1604656A1 (de) 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von amyotropher Lateralsklerose (ALS)
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
PL1781276T3 (pl) * 2004-08-27 2010-11-30 Ucb Pharma Gmbh Zastosowanie związków peptydowych do leczenia bólu związanego z rakiem kości, bólu indukowanego przez chemioterapię oraz nukleozydy
EP1629839A1 (de) * 2004-08-27 2006-03-01 Schwarz Pharma Ag Verwendung von Peptidverbindungen zur Behandlung von Knochenkrebsschmerz sowie von Chemotherapie- oder Nukleosid-induziertem Schmerz
EP1642889A1 (de) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Verbessertes Syntheseschema für Lacosamid
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
KR20070096058A (ko) 2005-01-28 2007-10-01 쉬바르츠파르마에이지 정신분열증의 부가 요법용 ｓｐｍ 927
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1754476A1 (de) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamid (SPM 927) zur Behandlung von Myalgien, z.B. Fibromyalgie
CA2631675A1 (en) * 2005-11-30 2007-06-21 The University Of North Carolina At Chapel Hill Identification of genetic polymorphic variants associated with somatosensory disorders and methods of using the same
US7902401B2 (en) 2006-12-14 2011-03-08 Nps Pharmaceuticals, Inc. Fluorinated compounds
WO2007144195A2 (en) 2006-06-15 2007-12-21 Schwarz Pharma Ag Pharmaceutical composition with synergistic anticonvulsant effect
EP1920780A1 (de) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Peptidverbindungen zur Behandlung von Krankheiten mit erhöhter Erregbarkeit
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP1873527A1 (de) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Verfahren zur Identifizierung von CRMP-Modulatoren
CA2672494A1 (en) 2006-12-14 2008-06-19 Nps Pharmaceuticals, Inc. Use of d-serine derivatives for the treatment of anxiety disorders
MD3310G2 (ro) * 2006-12-27 2008-02-29 Ион МЕРЕУЦЭ Metodă de tratament al durerilor fantome
EP2214657A1 (de) * 2007-10-23 2010-08-11 UCB Pharma GmbH Verbindungen zur behandlung von demyelisationserkrankungen
CA2774569A1 (en) * 2009-09-23 2011-03-31 The University Of North Carolina At Chapel Hill Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
MX2013005974A (es) 2010-12-02 2013-07-29 Ucb Pharma Gmbh Formulacion de lacosamida de administracion una vez al dia.
EP2468261A1 (de) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulierung von Lacosamid
GB201200525D0 (en) * 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
KR20220147075A (ko) 2020-02-26 2022-11-02 에이지씨 가부시키가이샤 함불소 중합체, 막, 막의 제조 방법 및 유기 광전자 소자
FR3114739B1 (fr) * 2020-10-06 2022-08-26 Centre Nat Rech Scient Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2937698A1 (de) * 1979-09-18 1981-04-02 A. Nattermann & Cie GmbH, 5000 Köln N-propionylsarcosinanilide, deren herstellungsverfahren und arzneimittel auf deren basis
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4533657A (en) * 1981-07-24 1985-08-06 Sterling Drug Inc. Analgesic dipeptide amides and method of use and composition thereof
FR2518088B1 (fr) * 1981-12-16 1987-11-27 Roques Bernard Nouveaux derives d'aminoacides, et leur application therapeutique
US4510082A (en) * 1983-03-07 1985-04-09 Eli Lilly And Company Pharmacologically active peptides
JPH0680079B2 (ja) * 1984-11-09 1994-10-12 エーザイ株式会社 ポリペプチド
US5378729A (en) 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5654301A (en) 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
GB9103454D0 (en) 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
US5656267A (en) * 1991-08-22 1997-08-12 Sagen; Jacqueline Implantable cells that alleviate chronic pain in humans
TW217417B (de) 1991-12-04 1993-12-11 Manyu Seiyaku Kk
US5585358A (en) 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5536853A (en) * 1994-04-11 1996-07-16 Chiron Corporation Opiate receptor ligands
MY113062A (en) 1994-05-10 2001-11-30 The Wellcome Foundation Ltd Amide derivatives and their therapeutic use
US5508266A (en) * 1994-06-22 1996-04-16 Ciba-Geigy Corporation Gem-disubstituted amino acid derivatives
CZ288436B6 (en) 1994-10-05 2001-06-13 Darwin Discovery Ltd Peptidyl derivatives, their therapeutic use as inhibitors of metalloproteinases and pharmaceutical preparation in which they are comprised
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US5780589A (en) * 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
US5651301A (en) * 1994-12-13 1997-07-29 Unipat Aktiengessellschaft Hydrostatic piston machines
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5849737A (en) * 1995-04-14 1998-12-15 The Regents Of The University Of California Compositions and methods for treating pain
EP0840612A1 (de) * 1995-07-24 1998-05-13 Trustees Of Boston University Inhibierung der nmda rezeptoraktivitaet durch pregnolonsulfatderivate
TW450807B (en) * 1995-09-15 2001-08-21 Pfizer Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents
US6114390A (en) * 1995-11-30 2000-09-05 Karl Thomae Gmbh Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
DE19614542A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614533A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
DE19614534A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US6277825B1 (en) * 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
PL189872B1 (pl) * 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
US6589994B1 (en) 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
DE19636046A1 (de) 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
US6038324A (en) * 1997-02-21 2000-03-14 Ambourn; Paul R. Automotive surround sound circuit background of the invention
US6071966A (en) * 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
AU7937298A (en) 1997-07-08 1999-02-08 Ono Pharmaceutical Co. Ltd. Amino acid derivatives
US6737408B1 (en) * 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
WO1999007413A1 (en) 1997-08-11 1999-02-18 Algos Pharmaceutical Corporation Substance p inhibitors in combination with nmda-blockers for treating pain
DE19743143A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
WO1999023078A2 (de) 1997-10-31 1999-05-14 Basf Aktiengesellschaft Neue carbonsäurederivate, die amidseitenketten tragen, ihre herstellung und verwendung als endothelin-rezeptorantagonisten
US6492553B1 (en) * 1998-01-29 2002-12-10 Aventis Pharamaceuticals Inc. Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
US6028102A (en) 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
US6673832B1 (en) 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain
GB9812683D0 (en) * 1998-06-12 1998-08-12 Smithkline Beecham Plc Novel compounds
EP1137642B1 (de) 1999-09-03 2007-12-05 Actelion Pharmaceuticals Ltd. Bis-sulfonamiden
SE0001373D0 (sv) 2000-04-13 2000-04-13 Karolinska Innovations Ab NPY Y1 receptor agonists and antagonists
DK1311256T3 (da) 2000-08-17 2005-11-28 Teva Pharma Anvendelse af derivater af valproinsyreamider og 2-valproinsyreamider til behandling eller forebyggelse af smerter og/eller hovedpinelidelser
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
AU8676301A (en) * 2000-08-25 2002-03-04 Res Corp Technologies Inc New uses for amino acid anticonvulsants
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
AU2002224847A1 (en) 2000-11-21 2002-06-03 U C B, S.A. N-alkylated gaba compounds, processes for their preparation and their use as medicaments
DK1243262T3 (da) 2001-03-20 2006-10-02 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter
ES2185606T3 (es) 2001-03-21 2003-05-01 Sanol Arznei Schwarz Gmbh Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma.
IL157093A0 (en) 2001-03-27 2004-02-08 Actelion Pharmaceuticals Ltd 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
CA2445290A1 (en) 2001-04-26 2002-11-07 Chenkou Wei A pharmaceutical tablet having a high api content
ITMI20011308A1 (it) 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
AU2003243180A1 (en) * 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
ATE361289T1 (de) 2002-08-05 2007-05-15 Lilly Co Eli Piperazinsubstituierte arylbenzodiazepine
WO2004043926A1 (en) 2002-11-11 2004-05-27 Bayer Healthcare Ag Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
CA2544467C (en) 2002-11-18 2014-02-18 John M. Stewart Paralytic peptide for use in neuromuscular therapy
US7687080B2 (en) * 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US6991764B2 (en) * 2002-12-13 2006-01-31 Dade Behring Inc. Method for replacing used reaction cuvettes in an automatic analyzer depending upon next scheduled assay
EP1575563B1 (de) 2002-12-19 2007-02-14 Pharmacia Corporation Nicht-hygroskopische formulierung, die einen hygroskopischen wirkstoff enthält
WO2004066987A2 (en) 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
AU2004207010A1 (en) 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
WO2004100871A2 (en) 2003-05-09 2004-11-25 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US7307669B2 (en) * 2003-06-24 2007-12-11 Broadcom Corporation System, method, and apparatus for displaying streams with dynamically changing formats
US7320675B2 (en) * 2003-08-21 2008-01-22 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure
EP1537862A1 (de) 2003-12-02 2005-06-08 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von zentralen neuropathische-Schmerzen
JP4664924B2 (ja) 2003-12-02 2011-04-06 ウーツェーベー ファルマ ゲーエムベーハー 中枢神経因性疼痛の治療のためのペプチド化合物の新規使用
US20060009384A1 (en) 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
EP1541138A1 (de) 2003-12-05 2005-06-15 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Status Epilepticus und ähnlicher Zustände
US20070042969A1 (en) 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (de) 2004-03-26 2005-09-28 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von diabetishen Neuropathie
US20050227961A1 (en) * 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
KR20070007931A (ko) 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1598428A1 (de) * 2004-05-18 2005-11-23 Georg Dewald Verfahren und Kits zum Nachweis von erblichen angioedema typ III
EP1604654A1 (de) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Dyskynesien
EP1604656A1 (de) 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von amyotropher Lateralsklerose (ALS)
EP1604655A1 (de) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
PL1781276T3 (pl) * 2004-08-27 2010-11-30 Ucb Pharma Gmbh Zastosowanie związków peptydowych do leczenia bólu związanego z rakiem kości, bólu indukowanego przez chemioterapię oraz nukleozydy
EP1642889A1 (de) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Verbessertes Syntheseschema für Lacosamid
US20060252749A1 (en) 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1688137A1 (de) 2005-01-28 2006-08-09 Schwarz Pharma Ag SPM 927 zur Co-Therapie der Schizophrenie
US20070043120A1 (en) 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1754476A1 (de) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamid (SPM 927) zur Behandlung von Myalgien, z.B. Fibromyalgie
US20070048372A1 (en) 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
WO2007144195A2 (en) * 2006-06-15 2007-12-21 Schwarz Pharma Ag Pharmaceutical composition with synergistic anticonvulsant effect
EP1873527A1 (de) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Verfahren zur Identifizierung von CRMP-Modulatoren
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
JP4355003B2 (ja) * 2007-03-08 2009-10-28 本田技研工業株式会社 内燃機関の制御装置
EP2214657A1 (de) * 2007-10-23 2010-08-11 UCB Pharma GmbH Verbindungen zur behandlung von demyelisationserkrankungen
CN101841984A (zh) * 2009-03-19 2010-09-22 鸿富锦精密工业（深圳）有限公司 电子装置及其按键组件

Also Published As

Publication number Publication date
DE60100055D1 (de) 2003-01-09
SK12902003A3 (sk) 2004-06-08
SK287714B6 (en) 2011-07-06
EP1383487B1 (de) 2010-12-08
KR100557852B1 (ko) 2006-03-10
IL155585A0 (en) 2003-11-23
BR0208141A (pt) 2004-03-02
JP4154237B2 (ja) 2008-09-24
IL155585A (en) 2010-12-30
EA007600B1 (ru) 2006-12-29
ATE490766T1 (de) 2010-12-15
SI21169A (sl) 2003-10-31
ES2354417T3 (es) 2011-03-14
HUP0303983A3 (en) 2012-01-30
CA2430470C (en) 2008-11-04
HK1048763B (en) 2003-08-01
US7875652B2 (en) 2011-01-25
KR20030076604A (ko) 2003-09-26
ZA200303319B (en) 2003-07-08
ES2368317T3 (es) 2011-11-16
DK1243263T3 (da) 2003-03-17
NO20033918D0 (no) 2003-09-04
EP2201943A1 (de) 2010-06-30
US20040220077A1 (en) 2004-11-04
DE60100055T2 (de) 2003-07-24
AU2002257680B2 (en) 2006-12-14
EP1383487A1 (de) 2004-01-28
EP2201943B1 (de) 2011-08-03
PT1243263E (pt) 2003-03-31
SI21169B (sl) 2011-06-30
ES2185606T3 (es) 2003-05-01
EP1243263B1 (de) 2002-11-27
JP2004524337A (ja) 2004-08-12
HK1048763A1 (en) 2003-04-17
IL202688A0 (en) 2010-06-30
DE60238524D1 (de) 2011-01-20
EP1243263A1 (de) 2002-09-25
WO2002074297A1 (en) 2002-09-26
ATE518532T1 (de) 2011-08-15
CN1498104A (zh) 2004-05-19
US20110082211A1 (en) 2011-04-07
EA200300933A1 (ru) 2004-04-29
UA73854C2 (en) 2005-09-15
US20100099770A1 (en) 2010-04-22
NO20033918L (no) 2003-09-04
HUP0303983A2 (hu) 2004-04-28
PL368408A1 (en) 2005-03-21
CA2430470A1 (en) 2002-09-26
CN100522149C (zh) 2009-08-05
CZ20032798A3 (cs) 2007-06-20
MXPA03006438A (es) 2004-05-24

Similar Documents

Publication Publication Date Title
ATE490766T1 (de) Neue verwendung einer klasse von peptidverbindungen zur behandlung von allodynie oder andere arten von chronischen oder phatomschmerzen
EP1446136A4 (de) Curcuminoid-zusammensetzungen mit synergistischer hemmung der expression und/oder wirkung von cyclooxygenase-2
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
BR0212203A (pt) Composições e processos para tratamento de diabetes
ATE389411T1 (de) Strontium verbindung zur behandlung von sub- dermalem weichteilschmerz
DE60228761D1 (de) Pharmazeutische zusammensetzung (kit) enthaltend dihydropyridinonverbindungen und eine verbindung mit immunmodulatorischer (oder antiinflammatorischer) wirkung und ihre verwendung
NZ263344A (en) Human bactericidal/permeability increasing (bpi) protein functional domain peptides and their use
PT1171465E (pt) Analogos de petido inibidor gastrico e sua utilizacao para o tratamento de diabetes
BR9812837A (pt) Processo para fazer um composto, e, composto
CU23043A1 (es) Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
LU93259I2 (fr) LETIFEND (Protein Q)
BR0215395A (pt) Compostos; processo para a preparação de um composto; composição farmacêutica; e método para o tratamento e/ou profilaxia de doenças que estão relacionadas com o nìvel de glicose no sangue
DE60204584D1 (de) Zusammensetzungen enthaltend eine niedrige konzentration an peroxide zur behandlung von vaginitis
WO2003046205A3 (en) Methods for identifying modulators of apoptosis
ATE493125T1 (de) Carbamatverbindungen zur behandlung von schmerz
ATE268166T1 (de) Zusammenstellungen zur behandlung von lungenkrankheiten mit optisch reinem s-salmeterol
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
ATE506947T1 (de) Kondensierte thiophene verbindungen und deren verwendung zur behandlung von chronischen schmerzen
ATE382262T1 (de) Fungizide zusammensetzung auf der basis von saurem kaliumphosphit
HUP9701618A2 (hu) Tramadolt és valamely kálciumcsatorna antagonistát tartalmazó gyógyászati készítmény
DE60336417D1 (de) Flüssige zusammensetzungen mit 3,7-diazabicycloä3,3,1ü nonanen zur behandlung von anti-arrhythmischen ereignissen
ATE485831T1 (de) Behandlung von neurodegeneration
ATE235509T1 (de) Peptide zur inhibition von hpv e7 proteinen
ATE465175T1 (de) Neuer proteinkomplex und anwendungen davon
DE60233353D1 (de) Verfahren zur behandlung von halitose

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1243263

Country of ref document: EP

EEIH Change in the person of patent owner